Medications

FDA panel narrowly sides against experimental ALS drug

Federal health advisers on Wednesday narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig's disease, a potential setback for patient groups who have lobbied for the medication's approval.

Medications

Drug modifies epigenome in aggressive brain tumors

A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed a DNA process within their brain tumors, according to results from a phase 1 clinical ...

page 6 from 17